Skip to main content
SpringerLink
Log in

Darusentan in Resistant Hypertension: Lost in Translation

  • Clinical Trial Report
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mancia G, De Backer G, Dominiczak A, et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007, 28(12):1462–1536.

    PubMed  Google Scholar 

  2. Hypertension: uncontrolled and conquering the world [editorial]. Lancet 2007, 370(9587):539.

  3. Enseleit F, Luscher TF, Ruschitzka F: Darusentan: a new perspective for treatment of resistant hypertension? Expert Opin Investig Drugs 2008, 17(8):1255–1263.

    Article  CAS  PubMed  Google Scholar 

  4. Schrader J, Tebbe U, Borries M, et al.: [Plasma endothelin in normal probands and patients with nephrologic–rheumatologic and cardiovascular diseases]. Klin Wochenschr 1990, 68(15):774–779.

    Article  CAS  PubMed  Google Scholar 

  5. Saito Y, Nakao K, Mukoyama M, Imura H: Increased plasma endothelin level in patients with essential hypertension. N Engl J Med 1990, 322(3):205.

    CAS  PubMed  Google Scholar 

  6. Krum H, Viskoper RJ, Lacourciere Y, et al.: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998, 338(12):784–790.

    Article  CAS  PubMed  Google Scholar 

  7. Nakov R, Pfarr E, Eberle S: Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 2002, 15(7 Pt 1):583–589.

    Article  CAS  PubMed  Google Scholar 

  8. Black HR, Bakris GL, Weber MA, et al.: Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 2007, 9(10):760–769.

    Article  CAS  Google Scholar 

  9. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ: The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008, 153(6):1105–1119.

    Article  CAS  PubMed  Google Scholar 

  10. Spieker LE, Mitrovic V, Noll G, et al.: Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol 2000, 35(7):1745–1752.

    Article  CAS  PubMed  Google Scholar 

  11. Luscher TF, Enseleit F, Pacher R, et al.: Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002, 106(21):2666–2672.

    Article  PubMed  Google Scholar 

  12. Anand I, McMurray J, Cohn JN, et al.: Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364(9431):347–354.

    Article  CAS  PubMed  Google Scholar 

  13. Second pivotal phase III study of Gilead’s darusentan for resistant hypertension misses primary endpoints [press release]. Foster City, CA: Gilead Sciences, Inc; December 14, 2009. Available at http://www.gilead.com/pr_1365747. Accessed December 17, 2009.

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Cardiovascular Center Cardiology, University Hospital Zurich, Rämistrasse 100, 8091, Zürich, Switzerland

    Frank Enseleit & Frank Ruschitzka

Authors
  1. Frank Enseleit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Ruschitzka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank Enseleit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Enseleit, F., Ruschitzka, F. Darusentan in Resistant Hypertension: Lost in Translation. Current Science Inc 12, 1–3 (2010). https://doi.org/10.1007/s11906-009-0081-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-009-0081-y

Keywords

Search

Navigation